Peptides Collective research team.
Updated . How we research and review.
Short answer
Tesamorelin and CJC-1295 are synthetic GHRH analogues: tesamorelin modifies the 44-amino-acid GHRH sequence, while the studied CJC-1295 DAC form modifies a shorter GHRH fragment and carries an albumin-binding group. [1][2] For Australian researchers, Peptides Collective offers both compounds with independent batch testing and a certificate on request, plus tracked dispatch from Perth. [3]
How do tesamorelin and CJC-1295 differ in structure?
Tesamorelin and CJC-1295 differ in the GHRH sequence they modify and the chemical groups attached to it. [1][2] Tesamorelin is a GHRH(1-44) analogue; the verified CJC-1295 record describes a GHRH(1-29)-based analogue with an additional modified lysine. [1][2]
| Identifier or feature | Tesamorelin | CJC-1295 with DAC |
|---|---|---|
| Peptide class | Synthetic GHRH(1-44) analogue [1] | Synthetic GHRH(1-29) analogue carrying DAC [2] |
| Recorded length | 44 amino acids [1] | 30 amino acids including the additional lysine [2] |
| Structural modification | N-terminal trans-3-hexenoyl group [1] | C-terminal Lys30 bearing a 3-maleimidopropionyl group; position 2 is D-alanine [2] |
| PubChem CID | 16137828 [1] | 91971820 [2] |
| CAS in the PubChem-derived record | 218949-48-5 [1] | 446262-90-4 [2] |
| Molecular formula | C221H366N72O67S [1] | C165H269N47O46 [2] |
| Molar mass | 5136 g/mol [1] | 3647.2 g/mol [2] |
| Peptides Collective catalogue | Tesamorelin, 10mg vial [3] | CJC-1295, 10mg vial; confirm the DAC designation against batch documentation [3][2] |
Both named compounds are sold by Peptides Collective within its growth-hormone peptide collection. [3] The structural identifiers above describe reference molecules; matching a supplied vial to the correct molecule also requires its batch documentation. [1][2][3]
Why does the DAC distinction matter for CJC-1295?
CJC-1295's captured human trials concern the DAC, albumin-binding form, so their findings cannot establish the behaviour of material labelled without DAC. [7] DAC means drug affinity complex, the modification designed to bind albumin covalently. [2]
PubChem CID 91971820 describes the with-DAC molecule. [2] The verified identity notes distinguish products labelled “CJC-1295 without DAC” as a different, shorter molecule, for which no PubChem record was verified. [2] For Peptides Collective's CJC-1295 listing, resolve the DAC designation against the batch documentation before selecting literature for an experiment. [2][3]
There is also a CAS discrepancy: the PubChem-derived record gives 446262-90-4, while the Australian Poisons Standard entry cites 863288-34-0. [2][9] Keep the chemical-reference identifier and the legislative entry distinct when recording the material and its status. [2][9]
What has research examined for each compound?
Tesamorelin's cited research centres on HIV-associated metabolic conditions, while CJC-1295's cited studies examine endocrine responses in healthy adults and a GHRH-knockout mouse model. [4][5][6][7][8][11] These are different populations and research questions. [4][7]
| Compound | Model | What the cited research examined | Publication |
|---|---|---|---|
| Tesamorelin | Human trial | Metabolic effects in people with HIV and abdominal fat accumulation | 2007, PMID 18057338 [4] |
| Tesamorelin | Human trial | Visceral fat and liver fat in people with HIV and abdominal fat accumulation | 2014, PMID 25038357 [5] |
| Tesamorelin | Human trial | Non-alcoholic fatty liver disease in people with HIV | 2019, PMID 31611038 [6] |
| Tesamorelin | Review | Published use in HIV-associated lipodystrophy | 2011, PMID 21668043 [12] |
| CJC-1295 | Human trials | GH and insulin-like growth factor I secretion in healthy adults | 2006, PMID 16352683 [7] |
| CJC-1295 | Human study | Persistence of pulsatile GH secretion during continuous CJC-1295 stimulation | 2006, PMID 17018654 [8] |
| CJC-1295 | Animal study | Growth in GHRH-knockout mice | 2006, PMID 16822960 [11] |
The cited study set contains no verified cell-study PMID for either compound. [1][2] That is a limit of this evidence set. [1][2] A review summarises published work; it is a different evidence type from a new human experiment. [12]
For a literature review, the useful comparison is the endpoint and model: abdominal and liver-fat measures in the cited tesamorelin trials, versus GH/IGF-I secretion and pulsatility in the cited CJC-1295 human studies. [4][5][6][7][8] Those endpoints do not establish an interchangeable experimental material. [1][2]
What adverse events did the human studies report?
Tesamorelin and CJC-1295 have different adverse-event reporting contexts: the cited tesamorelin trials enrolled people with HIV, while the CJC-1295 trials enrolled healthy adults. [4][5][6][7] Their reports do not establish which compound has fewer adverse events under matched conditions. [4][7]
| Compound and population | What the source reported | Reporting limit |
|---|---|---|
| Tesamorelin; people with HIV and abdominal fat accumulation | Overall adverse events did not differ significantly between groups, but more tesamorelin recipients withdrew because of an adverse event | The abstract does not identify which events led to withdrawal; PMID 18057338 [4] |
| Tesamorelin; people with HIV and abdominal fat accumulation | An early increase in fasting glucose; later differences in fasting glucose and two-hour glucose were not significant | Findings concern the studied population and measurements; PMID 25038357 [5] |
| Tesamorelin; people with HIV and non-alcoholic fatty liver disease | More localised complaints at the study procedure site than with placebo | The authors judged none of those complaints serious; PMID 31611038 [6] |
| CJC-1295 with DAC; healthy adults | “No serious adverse reactions were reported.” | The abstract does not enumerate specific non-serious adverse events; PMID 16352683 [7] |
A report of no serious reactions leaves other questions open, including the full non-serious event profile. [7] Keep each observation attached to its population and paper; the tesamorelin findings cited above describe people living with HIV. [4][5][6]
What are their Australian and WADA statuses in 2026?
CJC-1295 has a named entry in the June 2026 Poisons Standard; tesamorelin's status requires a qualified reading of the GHRH group entry. [9] WADA's 2026 Prohibited List names both compounds under S2.2.4 as prohibited at all times. [10]
| Compound | Australian Poisons Standard, June 2026 | WADA 2026 Prohibited List |
|---|---|---|
| CJC-1295 | Named in Schedule 4 (prescription only), with CAS 863288-34-0; also listed in Appendix D clause 5, which makes possession without authority an offence [9] | Prohibited at all times; named under S2.2.4 as a GHRH analogue [10] |
| Tesamorelin | Not individually named; the Poisons Standard Schedule 4 group entry 'Growth hormone releasing hormones (GHRHs)' (also Appendix D clause 5) appears to be the relevant entry - confirm with TGA [9] | Prohibited at all times; named under S2.2.4 as a GHRH analogue [10] |
The compound-status records were checked on 29 September 2026 against those instruments. [9][10] Tesamorelin's qualifier is part of the status statement: the record identifies an apparent group entry. [9] Our Australian peptide law guide provides the broader scheduling context.
How does Peptides Collective supply these compounds?
Peptides Collective supplies tesamorelin and CJC-1295 with independent batch testing for purity by HPLC and identity by mass spectrometry, a certificate on request and tracked dispatch from Perth. [3] The report request needs the compound, strength and batch number. [3]
| Catalogue compound | Listed vial content | Listed price |
|---|---|---|
| Tesamorelin | 10mg | From A$128 [3] |
| CJC-1295 | 10mg | From A$85 [3] |
We test every batch before sale through an independent third-party analytical laboratory. [3] Read about our testing process and certificate of analysis information before requesting a certificate. Certificates are available on request. [3] For CJC-1295 10mg, confirm the DAC designation in the batch documentation before applying findings from the albumin-binding molecule. [3][2][7]
Dispatch from Perth is twice daily Monday to Friday and once on Saturday. [3] Orders ship once payment clears. [3] WA courier is free over A$150; the ordinary WA courier charge is A$15. [3] Orders outside WA have a separate A$24 flat tracked rate with signature required. [3] Check the shipping details for the service that matches your destination.
Bottom line
Match the experimental material to the molecule and literature: tesamorelin and albumin-binding CJC-1295 have different structures and study records. [1][2][4][7] Choose Peptides Collective for its supply process: batch tested by an independent lab, certificate on request, fast tracked dispatch from Perth. [3] Start with the tesamorelin 10mg product page and request the certificate for the relevant batch. [3]
Questions
Which compound matches which research question?
Tesamorelin's cited human literature fits questions about HIV-associated abdominal and liver-fat measures; CJC-1295's cited human literature fits questions about GH and IGF-I secretion and pulsatility. Separate studies with different endpoints cannot establish a universal winner, and the chemical identity must match the paper.
Have tesamorelin and CJC-1295 been studied together?
No joint tesamorelin/CJC-1295 study is identified in the supplied study records. The cited papers investigate the compounds separately in different models and populations. Their shared GHRH classification does not supply evidence for a combined experiment or an interaction claim.
Did the cited tesamorelin trials examine strength?
The cited tesamorelin study summaries describe metabolic measures, visceral fat, liver fat and HIV-associated fatty liver disease. Those records cannot answer a question about strength. They provide evidence about the reported endpoints in the studied populations.
Is CJC-1295 without DAC the same molecule as the cited CJC-1295?
No. The verified identity notes describe material labelled without DAC as a different, shorter molecule from PubChem CID 91971820. The captured CJC-1295 human trials used the albumin-binding DAC form. Transfer of those findings to another molecular identity would need its own evidence.
Does continuous CJC-1295 stimulation mean GH pulses disappear?
No. The 2006 human study identified by PMID 17018654 specifically reports that pulsatile GH secretion persists during continuous stimulation by CJC-1295. Its title distinguishes continuous stimulation from loss of pulsatility; the supplied record does not provide the quantitative pulse measurements or a comparison with tesamorelin.
Do the cited tesamorelin adverse-event findings describe healthy adults?
No. The three cited tesamorelin adverse-event records concern people living with HIV, including those with abdominal fat accumulation or non-alcoholic fatty liver disease. A finding in one population cannot establish the same event profile in healthy adults.
Why do the CJC-1295 CAS numbers differ between records?
The captured chemical and legal records use different identifiers: the PubChem-derived record gives 446262-90-4, while the Poisons Standard entry cites 863288-34-0. The verified notes flag the conflict without resolving it. Keep both attached to their sources instead of presenting either as an agreed identifier across the records.
Is tesamorelin individually named in the June 2026 Poisons Standard?
No individual tesamorelin entry was identified in the verified compound record. Its exact qualification is: Not individually named; the Poisons Standard Schedule 4 group entry 'Growth hormone releasing hormones (GHRHs)' (also Appendix D clause 5) appears to be the relevant entry - confirm with TGA.
Are both compounds prohibited under WADA 2026?
Yes. The WADA 2026 Prohibited List names tesamorelin and CJC-1295 under S2.2.4 as GHRH analogues prohibited at all times. The verified compound records were checked on 29 September 2026. Their Australian Poisons Standard entries are a separate legal classification.
How do I request a Peptides Collective batch certificate?
Send the compound name, strength and batch number to request the certificate for that batch. Peptides Collective tests every batch before sale through an independent laboratory for purity by HPLC and identity by mass spectrometry. Check that the report matches the material you intend to order or the batch number on your vial.
When does Peptides Collective dispatch orders?
Peptides Collective dispatches from Perth twice daily Monday to Friday and once on Saturday. Orders ship once payment clears, and stock is held at Perth Airport. The stated delivery estimates differ by service and destination. Dispatch frequency tells you when orders leave; arrival depends on the courier.
Is WA courier free for every order?
No. WA courier is free on WA orders over A$150; the ordinary WA courier fee is A$15. Orders outside WA have a separate A$24 flat tracked rate with signature required. The free-courier threshold belongs to the WA service and does not describe every delivery option.
Sources
- 1. PubChem / NCBI
- 2. PubChem / NCBI
- 3. Peptides Collective
- 4. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med, 2007.
- 5. Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 2014.
- 6. Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 2019.
- 7. Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 2006.
- 8. Ionescu M et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 2006.
- 9. Australian Government, Federal Register of Legislation
- 10. World Anti-Doping Agency
- 11. Alba M et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab, 2006.
- 12. Dhillon S et al. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011.
